• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

    2/13/24 5:08:02 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care
    Get the next $LMAT alert in real time by email
    SC 13G/A 1 tv01326-lemaitrevascularinc.htm SCHEDULE 13G/A lemaitrevascularinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 5)*

    Name of issuer:  LeMaitre Vascular Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  525558201

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  525558201

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    36,692

    7.  SOLE DISPOSITIVE POWER

    1,494,432

    8.  SHARED DISPOSITIVE POWER

    54,438

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,548,870

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.96%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    LeMaitre Vascular Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    63 Second Avenue
    Burlington, MA 01803

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    525558201

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $LMAT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LMAT

    DatePrice TargetRatingAnalyst
    8/6/2025$95.00Mkt Perform → Outperform
    Barrington Research
    2/28/2025Outperform → Perform
    Oppenheimer
    2/28/2025Outperform → Mkt Perform
    Barrington Research
    2/13/2025$95.00Equal Weight
    Wells Fargo
    10/15/2024$96.00Neutral
    Cantor Fitzgerald
    8/2/2024$85.00 → $105.00Buy
    Lake Street
    5/31/2024$100.00Buy
    ROTH MKM
    4/26/2024$59.00 → $75.00Hold → Buy
    Stifel
    More analyst ratings

    $LMAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LeMaitre Q2 2025 Financial Results

    BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q2 2025: Sales $64.2mm, +15% (+15% organic)Gross margin 70.0%, +110 bpsOp. income $16.1mm, +12%Op. margin 25%Earnings per diluted share $0.60, +16%Cash up $16.9mm sequentially to $319.5mm Catheters (+27%) and grafts (+19%) drove Q2 sales growth. EMEA sales increased 23%, Americas 12%, and APAC 12%. Price accounted for 8% of sales growth and units 7%. Gross margin of 70.0% (vs. 68.9% in Q2 2024) increased due to higher average selling prices

    8/5/25 4:05:16 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025

    BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at ir.lemaitre.com. About LeMaitre LeMaitre is a provider of devices, implants, and services fo

    7/8/25 4:04:39 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    $LMAT
    SEC Filings

    View All

    SEC Form 144 filed by LeMaitre Vascular Inc.

    144 - LEMAITRE VASCULAR INC (0001158895) (Subject)

    8/8/25 4:22:15 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by LeMaitre Vascular Inc.

    10-Q - LEMAITRE VASCULAR INC (0001158895) (Filer)

    8/6/25 6:06:10 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Vascular Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)

    8/5/25 4:22:59 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jasinski Lawrence J sold $90,553 worth of shares (976 units at $92.78), decreasing direct ownership by 17% to 4,773 units (SEC Form 4)

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    8/14/25 4:30:07 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    President and Director Roberts David B exercised 10,815 shares at a strike of $37.27 and sold $999,173 worth of shares (10,815 units at $92.39) (SEC Form 4)

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    8/13/25 5:08:21 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Director Ross Bridget A exercised 2,500 shares at a strike of $37.29 and sold $235,000 worth of shares (2,500 units at $94.00) (SEC Form 4)

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    8/13/25 8:55:24 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lemaitre Vascular upgraded by Barrington Research with a new price target

    Barrington Research upgraded Lemaitre Vascular from Mkt Perform to Outperform and set a new price target of $95.00

    8/6/25 7:37:02 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Lemaitre Vascular downgraded by Oppenheimer

    Oppenheimer downgraded Lemaitre Vascular from Outperform to Perform

    2/28/25 8:28:09 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Lemaitre Vascular downgraded by Barrington Research

    Barrington Research downgraded Lemaitre Vascular from Outperform to Mkt Perform

    2/28/25 7:39:54 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Leadership Updates

    Live Leadership Updates

    View All

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

    GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

    3/20/25 9:00:00 AM ET
    $LMAT
    $POCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Former Johnson & Johnson Executive Joins Advisory Board at Maitri Health Technologies

    Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and

    3/23/21 8:00:00 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Financials

    Live finance-specific insights

    View All

    LeMaitre Q2 2025 Financial Results

    BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q2 2025: Sales $64.2mm, +15% (+15% organic)Gross margin 70.0%, +110 bpsOp. income $16.1mm, +12%Op. margin 25%Earnings per diluted share $0.60, +16%Cash up $16.9mm sequentially to $319.5mm Catheters (+27%) and grafts (+19%) drove Q2 sales growth. EMEA sales increased 23%, Americas 12%, and APAC 12%. Price accounted for 8% of sales growth and units 7%. Gross margin of 70.0% (vs. 68.9% in Q2 2024) increased due to higher average selling prices

    8/5/25 4:05:16 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025

    BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at ir.lemaitre.com. About LeMaitre LeMaitre is a provider of devices, implants, and services fo

    7/8/25 4:04:39 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Q1 2025 Financial Results

    BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic)Gross margin 69.2%, +60 bpsOp. income $12.6mm, +6%Op. margin 21%Earnings per diluted share $0.48, +10%Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm wa

    5/1/25 4:05:32 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by LeMaitre Vascular Inc.

    SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)

    10/22/24 3:49:21 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

    SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

    2/13/24 5:08:02 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

    SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

    2/12/24 3:02:21 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care